Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Amlitelimab in Moderate to Severe Atopic Dermatitis
NCT05769777Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Apr 2023
- Primary completion
- Jun 2031
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
Phase 2, open-label, single-arm trial of amlitelimab in atopic dermatitis (AD), sponsored by Sanofi. Primary endpoints: Treatment-Emergent Adverse Events at Week 284 and Treatment-Emergent Serious Adverse Events at Week 284. Started Apr 2023; status: active, not recruiting.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05769777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05769777.